Impact of cardiovascular risk factors in antiphospholipid syndrome: an observational study from the Spanish national registry
To determine the burden and impact of cardiovascular risk factors (CRF) in antiphospholipid syndrome (APS) patients. Analysis of the patients diagnosed with APS identified in the Spanish Hospital Discharge Database between 2016 and 2017. We analysed the admissions due to arterial (ATE) and venous th...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental rheumatology 2022-11, Vol.40 (11), p.2161-2166 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2166 |
|---|---|
| container_issue | 11 |
| container_start_page | 2161 |
| container_title | Clinical and experimental rheumatology |
| container_volume | 40 |
| creator | Moreno-Torres, Víctor Royuela, Ana Tarín, Carlos Castejón, Raquel Gutiérrez-Rojas, Ángela Durán-Del Campo, Pedro Mellor-Pita, Susana Tutor-Ureta, Pablo Sánchez, Enrique Martínez-Urbistondo, María de Mendoza, Carmen Vargas-Núñez, Juan-Antonio Ruiz-Irastorza, Guillermo |
| description | To determine the burden and impact of cardiovascular risk factors (CRF) in antiphospholipid syndrome (APS) patients.
Analysis of the patients diagnosed with APS identified in the Spanish Hospital Discharge Database between 2016 and 2017. We analysed the admissions due to arterial (ATE) and venous thromboembolic events (VTE) and evaluated the incidence and the attributed risk of each CRF.
5424 admissions in patients diagnosed with APS were identified. 64.6% were women and the mean age was 54.6. The mortality rate was 3.1%. Overall, 35.8% of patients had hypertension, 14% were diabetic, 21.7% hypercholesterolaemic, 9.9% obese and 26.7% smokers. Thromboembolic events (67.9% arterial and 32.1% venous) accounted for 11.9% of admissions and 7.1% of deaths. Male sex (OR 1.83, 95% CI 1.41-2.21), cholesterol (OR 1.25, 95% CI 1.01-1.54) and smoking (OR 1.49, 95% CI 1.22-1.81) were independently associated with thromboembolic events. Meanwhile, patients with ATE were older (57 vs. 54.1 years p=0.033), and presented more secondary APS (17.1% vs. 10.6%, p=0.034), hypertension (47.7% vs. 33.5%, p=0.001), diabetes (16.9% vs. 9.6%, p=0.017), cholesterol (34.3% vs. 17.8%, p |
| doi_str_mv | 10.55563/clinexprheumatol/h2tkx3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2635474198</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2635474198</sourcerecordid><originalsourceid>FETCH-LOGICAL-c315t-797eb61aa42a81624c9d0a45c9d8bf2c8245c61bdb808921a0503ee09dcc72d43</originalsourceid><addsrcrecordid>eNpdkE9L5TAUxYMo-nz6FYYs3XTMn6ZN3Q2ijiC40IG3K7dJOo22TSc3Fd_C7z7Fpy5cXM6Fc8698COEcvZTKVXIc9P70b1OsXPzACn0551Iz69yj6y4qmTGKr3ZJysmK5FpVWyOyDHiE2OiUEV5SI6kElKXSq7I2-0wgUk0tNRAtD68AJq5h0ijx2faLl6ISP1IYUx-6gIu0_vJW4rb0cYwuIvFoqFBF18g-TBCTzHNdkvbxaWpc_RhgtFjR8dPP7q_HlPcnpCDFnp0px-6Jn-urx4vf2d39ze3l7_uMiO5SllZla4pOEAuQPNC5KayDHK1iG5aYbRY9oI3ttFMV4IDU0w6xyprTClsLtfkbHd3iuHf7DDVg0fj-h5GF2asRSFVXua80ktU76ImBsTo2nqKfoC4rTmr3-HX3-HXO_hL9cfHl7kZnP0qftKW_wGTeovV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2635474198</pqid></control><display><type>article</type><title>Impact of cardiovascular risk factors in antiphospholipid syndrome: an observational study from the Spanish national registry</title><source>Alma/SFX Local Collection</source><creator>Moreno-Torres, Víctor ; Royuela, Ana ; Tarín, Carlos ; Castejón, Raquel ; Gutiérrez-Rojas, Ángela ; Durán-Del Campo, Pedro ; Mellor-Pita, Susana ; Tutor-Ureta, Pablo ; Sánchez, Enrique ; Martínez-Urbistondo, María ; de Mendoza, Carmen ; Vargas-Núñez, Juan-Antonio ; Ruiz-Irastorza, Guillermo</creator><creatorcontrib>Moreno-Torres, Víctor ; Royuela, Ana ; Tarín, Carlos ; Castejón, Raquel ; Gutiérrez-Rojas, Ángela ; Durán-Del Campo, Pedro ; Mellor-Pita, Susana ; Tutor-Ureta, Pablo ; Sánchez, Enrique ; Martínez-Urbistondo, María ; de Mendoza, Carmen ; Vargas-Núñez, Juan-Antonio ; Ruiz-Irastorza, Guillermo</creatorcontrib><description>To determine the burden and impact of cardiovascular risk factors (CRF) in antiphospholipid syndrome (APS) patients.
Analysis of the patients diagnosed with APS identified in the Spanish Hospital Discharge Database between 2016 and 2017. We analysed the admissions due to arterial (ATE) and venous thromboembolic events (VTE) and evaluated the incidence and the attributed risk of each CRF.
5424 admissions in patients diagnosed with APS were identified. 64.6% were women and the mean age was 54.6. The mortality rate was 3.1%. Overall, 35.8% of patients had hypertension, 14% were diabetic, 21.7% hypercholesterolaemic, 9.9% obese and 26.7% smokers. Thromboembolic events (67.9% arterial and 32.1% venous) accounted for 11.9% of admissions and 7.1% of deaths. Male sex (OR 1.83, 95% CI 1.41-2.21), cholesterol (OR 1.25, 95% CI 1.01-1.54) and smoking (OR 1.49, 95% CI 1.22-1.81) were independently associated with thromboembolic events. Meanwhile, patients with ATE were older (57 vs. 54.1 years p=0.033), and presented more secondary APS (17.1% vs. 10.6%, p=0.034), hypertension (47.7% vs. 33.5%, p=0.001), diabetes (16.9% vs. 9.6%, p=0.017), cholesterol (34.3% vs. 17.8%, p<0.001) and smoking habit (41.2% vs. 24%, p<0.001) when compared with VTE. Risk factors independently associated with ATE events were male sex (OR=1.61, 95% CI=1.30-2.03), hypertension (OR=1.30, 95% CI=1.03-1.64), cholesterol (OR=1.51, 95% CI=1.18-1.94) and smoking habit (OR=1.84, 95% CI=1.47-2.32), while VTE events were determined by male sex (OR=2.06, 95% CI=1.53-2.77) and obesity (OR=1.61, CI=1.02-2.52).
Thromboembolic events in APS were in part determined by a high prevalence of CRF. The identification of distinct profiles may allow us to undertake a more personalised approach to reduce thromboembolic events and to individualise anticoagulant and antiplatelet therapy.</description><identifier>ISSN: 0392-856X</identifier><identifier>ISSN: 1593-098X</identifier><identifier>EISSN: 1593-098X</identifier><identifier>DOI: 10.55563/clinexprheumatol/h2tkx3</identifier><identifier>PMID: 35238753</identifier><language>eng</language><publisher>Italy</publisher><ispartof>Clinical and experimental rheumatology, 2022-11, Vol.40 (11), p.2161-2166</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c315t-797eb61aa42a81624c9d0a45c9d8bf2c8245c61bdb808921a0503ee09dcc72d43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35238753$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moreno-Torres, Víctor</creatorcontrib><creatorcontrib>Royuela, Ana</creatorcontrib><creatorcontrib>Tarín, Carlos</creatorcontrib><creatorcontrib>Castejón, Raquel</creatorcontrib><creatorcontrib>Gutiérrez-Rojas, Ángela</creatorcontrib><creatorcontrib>Durán-Del Campo, Pedro</creatorcontrib><creatorcontrib>Mellor-Pita, Susana</creatorcontrib><creatorcontrib>Tutor-Ureta, Pablo</creatorcontrib><creatorcontrib>Sánchez, Enrique</creatorcontrib><creatorcontrib>Martínez-Urbistondo, María</creatorcontrib><creatorcontrib>de Mendoza, Carmen</creatorcontrib><creatorcontrib>Vargas-Núñez, Juan-Antonio</creatorcontrib><creatorcontrib>Ruiz-Irastorza, Guillermo</creatorcontrib><title>Impact of cardiovascular risk factors in antiphospholipid syndrome: an observational study from the Spanish national registry</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>To determine the burden and impact of cardiovascular risk factors (CRF) in antiphospholipid syndrome (APS) patients.
Analysis of the patients diagnosed with APS identified in the Spanish Hospital Discharge Database between 2016 and 2017. We analysed the admissions due to arterial (ATE) and venous thromboembolic events (VTE) and evaluated the incidence and the attributed risk of each CRF.
5424 admissions in patients diagnosed with APS were identified. 64.6% were women and the mean age was 54.6. The mortality rate was 3.1%. Overall, 35.8% of patients had hypertension, 14% were diabetic, 21.7% hypercholesterolaemic, 9.9% obese and 26.7% smokers. Thromboembolic events (67.9% arterial and 32.1% venous) accounted for 11.9% of admissions and 7.1% of deaths. Male sex (OR 1.83, 95% CI 1.41-2.21), cholesterol (OR 1.25, 95% CI 1.01-1.54) and smoking (OR 1.49, 95% CI 1.22-1.81) were independently associated with thromboembolic events. Meanwhile, patients with ATE were older (57 vs. 54.1 years p=0.033), and presented more secondary APS (17.1% vs. 10.6%, p=0.034), hypertension (47.7% vs. 33.5%, p=0.001), diabetes (16.9% vs. 9.6%, p=0.017), cholesterol (34.3% vs. 17.8%, p<0.001) and smoking habit (41.2% vs. 24%, p<0.001) when compared with VTE. Risk factors independently associated with ATE events were male sex (OR=1.61, 95% CI=1.30-2.03), hypertension (OR=1.30, 95% CI=1.03-1.64), cholesterol (OR=1.51, 95% CI=1.18-1.94) and smoking habit (OR=1.84, 95% CI=1.47-2.32), while VTE events were determined by male sex (OR=2.06, 95% CI=1.53-2.77) and obesity (OR=1.61, CI=1.02-2.52).
Thromboembolic events in APS were in part determined by a high prevalence of CRF. The identification of distinct profiles may allow us to undertake a more personalised approach to reduce thromboembolic events and to individualise anticoagulant and antiplatelet therapy.</description><issn>0392-856X</issn><issn>1593-098X</issn><issn>1593-098X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpdkE9L5TAUxYMo-nz6FYYs3XTMn6ZN3Q2ijiC40IG3K7dJOo22TSc3Fd_C7z7Fpy5cXM6Fc8698COEcvZTKVXIc9P70b1OsXPzACn0551Iz69yj6y4qmTGKr3ZJysmK5FpVWyOyDHiE2OiUEV5SI6kElKXSq7I2-0wgUk0tNRAtD68AJq5h0ijx2faLl6ISP1IYUx-6gIu0_vJW4rb0cYwuIvFoqFBF18g-TBCTzHNdkvbxaWpc_RhgtFjR8dPP7q_HlPcnpCDFnp0px-6Jn-urx4vf2d39ze3l7_uMiO5SllZla4pOEAuQPNC5KayDHK1iG5aYbRY9oI3ttFMV4IDU0w6xyprTClsLtfkbHd3iuHf7DDVg0fj-h5GF2asRSFVXua80ktU76ImBsTo2nqKfoC4rTmr3-HX3-HXO_hL9cfHl7kZnP0qftKW_wGTeovV</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Moreno-Torres, Víctor</creator><creator>Royuela, Ana</creator><creator>Tarín, Carlos</creator><creator>Castejón, Raquel</creator><creator>Gutiérrez-Rojas, Ángela</creator><creator>Durán-Del Campo, Pedro</creator><creator>Mellor-Pita, Susana</creator><creator>Tutor-Ureta, Pablo</creator><creator>Sánchez, Enrique</creator><creator>Martínez-Urbistondo, María</creator><creator>de Mendoza, Carmen</creator><creator>Vargas-Núñez, Juan-Antonio</creator><creator>Ruiz-Irastorza, Guillermo</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20221101</creationdate><title>Impact of cardiovascular risk factors in antiphospholipid syndrome: an observational study from the Spanish national registry</title><author>Moreno-Torres, Víctor ; Royuela, Ana ; Tarín, Carlos ; Castejón, Raquel ; Gutiérrez-Rojas, Ángela ; Durán-Del Campo, Pedro ; Mellor-Pita, Susana ; Tutor-Ureta, Pablo ; Sánchez, Enrique ; Martínez-Urbistondo, María ; de Mendoza, Carmen ; Vargas-Núñez, Juan-Antonio ; Ruiz-Irastorza, Guillermo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c315t-797eb61aa42a81624c9d0a45c9d8bf2c8245c61bdb808921a0503ee09dcc72d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moreno-Torres, Víctor</creatorcontrib><creatorcontrib>Royuela, Ana</creatorcontrib><creatorcontrib>Tarín, Carlos</creatorcontrib><creatorcontrib>Castejón, Raquel</creatorcontrib><creatorcontrib>Gutiérrez-Rojas, Ángela</creatorcontrib><creatorcontrib>Durán-Del Campo, Pedro</creatorcontrib><creatorcontrib>Mellor-Pita, Susana</creatorcontrib><creatorcontrib>Tutor-Ureta, Pablo</creatorcontrib><creatorcontrib>Sánchez, Enrique</creatorcontrib><creatorcontrib>Martínez-Urbistondo, María</creatorcontrib><creatorcontrib>de Mendoza, Carmen</creatorcontrib><creatorcontrib>Vargas-Núñez, Juan-Antonio</creatorcontrib><creatorcontrib>Ruiz-Irastorza, Guillermo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moreno-Torres, Víctor</au><au>Royuela, Ana</au><au>Tarín, Carlos</au><au>Castejón, Raquel</au><au>Gutiérrez-Rojas, Ángela</au><au>Durán-Del Campo, Pedro</au><au>Mellor-Pita, Susana</au><au>Tutor-Ureta, Pablo</au><au>Sánchez, Enrique</au><au>Martínez-Urbistondo, María</au><au>de Mendoza, Carmen</au><au>Vargas-Núñez, Juan-Antonio</au><au>Ruiz-Irastorza, Guillermo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of cardiovascular risk factors in antiphospholipid syndrome: an observational study from the Spanish national registry</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2022-11-01</date><risdate>2022</risdate><volume>40</volume><issue>11</issue><spage>2161</spage><epage>2166</epage><pages>2161-2166</pages><issn>0392-856X</issn><issn>1593-098X</issn><eissn>1593-098X</eissn><abstract>To determine the burden and impact of cardiovascular risk factors (CRF) in antiphospholipid syndrome (APS) patients.
Analysis of the patients diagnosed with APS identified in the Spanish Hospital Discharge Database between 2016 and 2017. We analysed the admissions due to arterial (ATE) and venous thromboembolic events (VTE) and evaluated the incidence and the attributed risk of each CRF.
5424 admissions in patients diagnosed with APS were identified. 64.6% were women and the mean age was 54.6. The mortality rate was 3.1%. Overall, 35.8% of patients had hypertension, 14% were diabetic, 21.7% hypercholesterolaemic, 9.9% obese and 26.7% smokers. Thromboembolic events (67.9% arterial and 32.1% venous) accounted for 11.9% of admissions and 7.1% of deaths. Male sex (OR 1.83, 95% CI 1.41-2.21), cholesterol (OR 1.25, 95% CI 1.01-1.54) and smoking (OR 1.49, 95% CI 1.22-1.81) were independently associated with thromboembolic events. Meanwhile, patients with ATE were older (57 vs. 54.1 years p=0.033), and presented more secondary APS (17.1% vs. 10.6%, p=0.034), hypertension (47.7% vs. 33.5%, p=0.001), diabetes (16.9% vs. 9.6%, p=0.017), cholesterol (34.3% vs. 17.8%, p<0.001) and smoking habit (41.2% vs. 24%, p<0.001) when compared with VTE. Risk factors independently associated with ATE events were male sex (OR=1.61, 95% CI=1.30-2.03), hypertension (OR=1.30, 95% CI=1.03-1.64), cholesterol (OR=1.51, 95% CI=1.18-1.94) and smoking habit (OR=1.84, 95% CI=1.47-2.32), while VTE events were determined by male sex (OR=2.06, 95% CI=1.53-2.77) and obesity (OR=1.61, CI=1.02-2.52).
Thromboembolic events in APS were in part determined by a high prevalence of CRF. The identification of distinct profiles may allow us to undertake a more personalised approach to reduce thromboembolic events and to individualise anticoagulant and antiplatelet therapy.</abstract><cop>Italy</cop><pmid>35238753</pmid><doi>10.55563/clinexprheumatol/h2tkx3</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0392-856X |
| ispartof | Clinical and experimental rheumatology, 2022-11, Vol.40 (11), p.2161-2166 |
| issn | 0392-856X 1593-098X 1593-098X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2635474198 |
| source | Alma/SFX Local Collection |
| title | Impact of cardiovascular risk factors in antiphospholipid syndrome: an observational study from the Spanish national registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T21%3A47%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20cardiovascular%20risk%20factors%20in%20antiphospholipid%20syndrome:%20an%20observational%20study%20from%20the%20Spanish%20national%20registry&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=Moreno-Torres,%20V%C3%ADctor&rft.date=2022-11-01&rft.volume=40&rft.issue=11&rft.spage=2161&rft.epage=2166&rft.pages=2161-2166&rft.issn=0392-856X&rft.eissn=1593-098X&rft_id=info:doi/10.55563/clinexprheumatol/h2tkx3&rft_dat=%3Cproquest_cross%3E2635474198%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2635474198&rft_id=info:pmid/35238753&rfr_iscdi=true |